fluticasone

(redirected from Flovent hfa)
Also found in: Dictionary, Wikipedia.
Related to Flovent hfa: Flovent Diskus

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.

fluticasone

/flu·tic·a·sone/ (floo-tik´ah-sōn″) a synthetic corticosteroid used as the propionate salt to treat inflammation in certain dermatoses, allergic rhinitis and other inflammatory nasal conditions, nasal polyps, and asthma.

fluticasone

[floo͡tik′äsōn′]
a steroid antiinflammatory agent, used topically as the propionate salt in treatment of itching or inflammation, intranasally in the treatment of allergic rhinitis and other inflammatory nasal conditions and of nasal polyps, and by inhalation in treatment of asthma.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
References in periodicals archive ?
Flovent HFA is an ICS that helps to reduce inflammation in the airways - one of the main components of asthma.
Flovent HFA 88 mcg twice daily improved peak expiratory flow, reduced daily rescue albuterol use, and reduced nighttime awakenings due to asthma as compared to placebo over 12 weeks in children four to 11 years of age with persistent asthma.
Flovent HFA is the last in the GlaxoSmithKline portfolio of respiratory products to be transitioned to a CFC-free reformulation in the United States.
Flovent HFA was approved by the Food & Drug Administration in May 2004 and is indicated for the maintenance treatment of asthma as a preventative therapy in patients 12 years of age and older.
In clinical trials of adults and adolescents, Flovent HFA demonstrated comparable safety and efficacy to the CFC Flovent product.
With the introduction of Flovent HFA, the CFC formulation of Flovent will be phased out of distribution by mid-March 2005.
The National Institutes of Health (NIH) and the American Academy of Pediatrics agree that low-doses of ICS medications, such as Flovent HFA 44 mcg or Flovent Diskus 50 mcg are preferred treatments for mild, persistent asthma in children.